Transplant Complications Working Party (TCWP)
Type d'étude:
Numéro de l'étude:
Type de traitement à base de cellules souches:
Allogeneic
Maladies:
Titre court:
Objectif principal:
The primary endpoint of the study was non-relapse mortality at two years after allo-SCT. Overall survival, relapse incidence, chronic (c) GvHD incidence at two years, acute (a) GVHD incidence, non-engraftment at day 30 after allo-SCT were selected as secondary endpoints.
Principaux critères d'inclusion:
Eligibility criteria included patients receiving a first allo-SCT using mobilized peripheral blood (PB) or bone marrow (BM) between 2005 – 2017.
Pays:
Investigateur principal:
Michal Gorka
Coordinateur EBMT de l'étude:
Emmanuelle Polge
E-mail du coordinateur de l'étude:
emmanuelle.polge@ebmt.org